Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey-Reference-Cited by-同舟云学术

Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey

Published:2018-03 Issue:2 Volume:4 Page:235-244
ISSN:2405-4569
Container-title:European Urology Focus
language:en
Short-container-title:European Urology Focus

Author:

Lorente David,Ravi Praful,Mehra Niven,Pezaro Carmel,Omlin Aurelius,Gilman Alexa,Miranda Miguel,Rescigno Pasquale,Kolinsky Michael,Porta Nuria,Bianchini Diletta,Tunariu Nina,Perez Raquel,Mateo Joaquin,Payne Heather,Terstappen Leon,IJzerman Maarten,Hall Emma,de Bono Johann

Publisher

Elsevier BV

Subject

Urology

Reference31 articles.

1. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

2. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013

3. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

4. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

5. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection;Journal of Nuclear Medicine;2024-05-09

2. Prognostic role of early prostate specific antigen changes after [¹⁷⁷Lu]Lu‐PSMA radioligand therapy of metastasized prostate cancer: A meta‐analysis;European Journal of Clinical Investigation;2023-05-17

3. Molecular predictors of metastasis in patients with prostate cancer;Expert Review of Molecular Diagnostics;2023-03-04

4. Association of Circulating Tumor Cells with Inflammatory and Biomarkers in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer;Life;2021-07-06

5. Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients;Cancers;2021-05-12